The Investor
28 Feb 2026, 17:37
SystImmune, Inc. and Bristol Myers Squibb reported positive interim Phase III results for izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).
In the China-based Phase III trial BL-B01D1-307 (NCT06382142), iza-bren met its dual primary endpoints of progression-free survival (PFS) and overall survival (OS) at a pre-specified interim analysis, demonstrating statistically significant and clinically meaningful improvements versus physician’s choice chemotherapy in patients whose disease progressed after prior taxane therapy.
Izalontamab brengitecan is an EGFR×HER3 bispecific antibody-drug conjugate (ADC). The study marks the third Phase III trial in which the therapy has achieved its primary endpoint(s) and represents the first bispecific ADC in a Phase III setting to report dual positive PFS and OS results in TNBC.
The companies said full data will be presented at an upcoming medical conference.
Source: Bristol Myers Squibb, Buiness Wire, February 26, 2026.
In the China-based Phase III trial BL-B01D1-307 (NCT06382142), iza-bren met its dual primary endpoints of progression-free survival (PFS) and overall survival (OS) at a pre-specified interim analysis, demonstrating statistically significant and clinically meaningful improvements versus physician’s choice chemotherapy in patients whose disease progressed after prior taxane therapy.
Izalontamab brengitecan is an EGFR×HER3 bispecific antibody-drug conjugate (ADC). The study marks the third Phase III trial in which the therapy has achieved its primary endpoint(s) and represents the first bispecific ADC in a Phase III setting to report dual positive PFS and OS results in TNBC.
The companies said full data will be presented at an upcoming medical conference.
Source: Bristol Myers Squibb, Buiness Wire, February 26, 2026.